BrevaRex

A phase-II trial, activated murine monoclonal antibody developed for treating tumours expressing MUC-1—e.g., breast, prostate, pancreas, renal, lung and colorectal cancers.

References in periodicals archive ?

BrevaRex MAb targets the tumor associated antigen MUC1 and has successfully completed a Phase I safety and immunology study.

Altarex licenses United States issued patents for autoimmune disease therapy

Ragupathy Madiyalakan, one of the founding executives of AltaRex, to the development of AltaRex's antibody directed immunotherapy program, which led to the discovery of OvaRex, Brevarex and Prostarex.

ViRexx Acknowledges Contribution of Former Executive

Additional findings for BrevaRex MAb (under development for multiple myeloma), GivaRex Mab (under development for gastrointestinal cancers), and ProstaRex MAb (under development for prostate cancer) illustrate the importance of using a foreign antibody that complexes with a circulating TAA.

Altarex awarded key foreign patent for Ait cancer technology

The Compnay's most advanced product, OvaRex MAb for ovarian cancer, is in two potentially pivotal Phase IIb clinical trials, while BrevaRex MAb is in a Phase I study.

AltaRex and Biomira announce settlement of lawsuits

The company's most advanced product, OvaRex MAb for ovarian cancer, is in two potentially pivotal Phase IIb clinical trials, while BrevaRex MAb has recently entered a Phase I study.